ArticleTranslational oncology2020
Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test.
Article in Translational oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2025Trial
- Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study.Cell reports. Medicine · 2024Trial
- High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancer.Journal of surgical oncology · 2022Trial
- Understanding and targeting the tumour matrisome.Nature reviews. Clinical oncology · 2026Review
- Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B).Breast cancer (Tokyo, Japan) · 2026Article
- De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trial.EClinicalMedicine · 2025Article
- Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling.NPJ precision oncology · 2025Article
- Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade.NPJ breast cancer · 2024Article
- B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.Breast cancer research : BCR · 2023Article
- BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.Breast cancer research : BCR · 2023Article
- Delineating intra-tumoral heterogeneity and tumor evolution in breast cancer using precision-based approaches.Frontiers in genetics · 2023Review
- Invasive Breast Cancer with HER2 ≥4.0 and <6.0: Risk Classification and Molecular Typing by a 21-Gene Expression Assay and MammaPrint Plus BluePrint Testing.Breast cancer (Dove Medical Press) · 2023Article
- Identifying Good Candidates for Active Surveillance of Ductal CarcinomaCancer research communications · 2022Observational
- Review
- Breast cancer in the era of precision medicine.Molecular biology reports · 2022Review
- BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance.Breast cancer research and treatment · 2022Article
- Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.Annals of surgical oncology · 2022Article
- Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.JCO precision oncology · 2022Article
- The clinical impacts of molecular subtyping by multigene assay on hormone receptor-positive breast cancers.Journal of the Chinese Medical Association : JCMA · 2022Article
- MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients.Genes, chromosomes & cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The analytical performance of a multi-gene diagnostic signature depends on many parameters, including precision, repeatability, reproducibility and intra-tumor heterogeneity. Here we study the analytical performance of the BluePrint 80-gene breast cancer molecular subtyping test through determination of these performance characteristics. BluePrint measures the expression of 80 genes that assess functional pathways which determine the intrinsic breast cancer molecular subtypes (i.e. Luminal-type, HER2-type, Basal-type). Knowing a tumor's dominant functional pathway can help allocate effective treatment to appropriate patients. Here we show that BluePrint is a highly precise and highly reproducible test with correlations above 98% based on the generated index and subtype concordance above 99%. Therefore, BluePrint can be used as a robust and reliable tool to identify breast cancer molecular subtypes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.